[{"id":"d3eed236-57f0-420e-a93f-39225269b5bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076396","created_at":"2021-10-13T16:58:16.690Z","updated_at":"2024-07-02T16:34:26.128Z","phase":"Phase 1","brief_title":"PM14 Administered Intravenously to Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05076396","lead_sponsor":"PharmaMar","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ecubectedin (PM14)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2024-06-14"},{"id":"b869532b-4b47-474d-a303-9692e3af1ab0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02838225","created_at":"2021-01-18T13:55:41.484Z","updated_at":"2024-07-02T16:37:30.412Z","phase":"Phase 2","brief_title":"DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer","source_id_and_acronym":"NCT02838225","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Pinorubin (pirarubicin) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 300","initiation":"Initiation: 01/01/2009","start_date":" 01/01/2009","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":"","study_completion_date":"","last_update_posted":"2016-07-20"}]